Benjamin, D. J. et al. The role of chemotherapy plus immune checkpoint inhibitors in oncogenic-driven NSCLC: a University of California lung cancer consortium retrospective study. JTO Clin. Res. Rep. 3, 100427 (2022).
Reck, M., Remon, J. & Hellmann, M. D. First-line immunotherapy for non-small-cell lung cancer. J. Clin. Oncol. 40, 586–597 (2022).
Martinez, P., Peters, S., Stammers, T. & Soria, J. C. Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 2691–2698 (2019).
Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >/= 50. J. Clin. Oncol. 39, 2339–2349 (2021).
Huang, M. Y., Jiang, X. M., Wang, B. L., Sun, Y. & Lu, J. J. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol. Ther. 219, 107694 (2021).
Meyer, M. L. et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 404, 803–822 (2024).
Kisamore, C. O., Elliott, B. D., DeVries, A. C., Nelson, R. J. & Walker, W. H. II Chronotherapeutics for solid tumors. Pharmaceutics 15, 2023 (2023).
Cermakian, N. & Labrecque, N. Regulation of cytotoxic CD8+ T cells by the circadian clock. J. Immunol. 210, 12–18 (2023).
Amiama-Roig, A., Verdugo-Sivianes, E. M., Carnero, A. & Blanco, J. R. Chronotherapy: circadian rhythms and their influence in cancer therapy. Cancers (Basel) 14, 5071 (2022).
Ince, L. M. et al. Influence of circadian clocks on adaptive immunity and vaccination responses. Nat. Commun. 14, 476 (2023).
Wang, C. L., Zhang, X. & Dang, C. V. Clocking cancer immunotherapy responses. Cancer Res. 84, 2756–2758 (2024).
Qian, D. C. et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 22, 1777–1786 (2021).
Patel, J. S. et al. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. J. Immunother. Cancer 12, e008011 (2024).
Ruiz-Torres, D. A. et al. Immunotherapy time of infusion impacts survival in head and neck cancer: a propensity score matched analysis. Oral Oncol. 151, 106761 (2024).
Nomura, M. et al. Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy. Esophagus 20, 722–731 (2023).
Hirata, T. et al. Brief report: clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC. JTO Clin. Res. Rep. 5, 100659 (2024).
Dizman, N. et al. Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma. Clin. Genitourin. Cancer 21, 530–536 (2023).
Landré, T. et al. Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open 9, 102220 (2024).
Karaboué, A. et al. Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy? Br. J. Cancer 131, 783–796 (2024).
Cortellini, A. et al. A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions. Ann. Oncol. 33, 1202–1204 (2022).
Rousseau, A. et al. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur. J. Cancer 182, 107–114 (2023).
Goss, G. et al. LBA48 CCTG BR.31: a global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Ann. Oncol. 35, S1238 (2024).
Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344–1357 (2021).
O’Brien, M. et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE–091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 23, 1274–1286 (2022).
Huang, Z. et al. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study. EBioMedicine 113, 105607 (2025).
Miao, K. et al. Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. Front. Immunol. 13, 912180 (2022).
Wang, Y., Zhu, J., Zhou, N., Wang, Y. & Zhang, X. Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study. J. Thorac. Dis. 15, 5669–5679 (2023).
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
Zhang, J. et al. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Clin. Cancer Res. 26, 1327–1337 (2020).
Marcos Rubio, A., Everaert, C., Van Damme, E., De Preter, K. & Vermaelen, K. Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer. J. Immunother. Cancer 11, e007023 (2023).
Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487–502.e415 (2017).
Wang, C. et al. Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. Cell 187, 2690–2702 (2024).
Fortin, B. M. et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat. Immunol. 25, 1257–1269 (2024).
Riely, G. J. et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 22, 249–274 (2024).
Kazandjian, D., Gong, Y., Keegan, P., Pazdur, R. & Blumenthal, G. M. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol. 5, 1481–1485 (2019).
Yeung, C., Kartolo, A., Tong, J., Hopman, W. & Baetz, T. Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma. Immunotherapy 15, 819–826 (2023).
Vilalta, A. et al. 967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer. Ann. Oncol. 32, S835 (2021).
Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).
Grambsch, P. M. & Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515–526 (1994).
Steinitz, O., Heller, J., Tsoar, A., Rotem, D. & Kadmon, R. Predicting regional patterns of similarity in species composition for conservation planning. Conserv. Biol. 19, 1978–1988 (2005).
Nekola, J. C. & White, P. S. The distance decay of similarity in biogeography and ecology. J. Biogeogr. 26, 867–878 (1999).
